Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Central South University59 enrolled

Overview

Evidence suggests that mGLUR5 availability may play a key role in the biology of mood disorders. This study aimed to investigate the changes in metabotropic glutamate receptor 5 (mGLUR5) availability and clinical symptoms in patients with MDD and bipolar disorder(BD) after two months of vortioxetine treatment. The investigators hypothesized that patients with MDD and BP have abnormal mGluR5 availability in certain brain regions, and baseline mGLUR5 availability can predict prognosis the prognosis of MDD and BD. fMRI and NODDI are also used to evaluate the function or neurite condition at baseline and 8 week

Study Type

OBSERVATIONAL

Enrollment

Conditions

Major Depressive Disorder Bipolar Disorder

Interventions

VortioxetineDRUG

All MDD patients will receive 5mg of Vortioxetine per day at the start of this study, which will be gradually increased to 10mg per day within one week.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Meet DSM-V criteria for a current depressive episode. * Being first-episode patients who were medication-naïve; * Score \>17 on 17-item Hamilton Depression Rating Scale (HDRS), score \>22 on Montgomery-Asberg Depression Rating Scale (MADRS), and score \<6 on Young Mania Rating Scale (YMRS). * Age 18 to 35. * Able to give written informed consent. Exclusion Criteria: * Have a current or past significant medical, neurological or metabolic disorder or head injury * Have active, significant suicidal ideation or past suicide attempts * Have implanted metallic devices or any MR contraindications * Are women who are pregnant or breastfeeding * Met DSM-5 criteria for substance use disorder * Met DSM-5 criteria for any current Axis I diagnosis (except Generalized Anxiety Disorder) * Are MDD patients present with delusions and/or hallucinations

Outcomes

Primary Outcomes

Baseline concentration of mGLUR5 availability

BPND at baseline as measured by PET

Time frame: Day 0

Change in concentration of mGLUR5 availability from baseline to 8 weeks

BPND changes from baseline to 8 weeks

Time frame: Week 8

Change of Hamilton Depression Rating Scale-17 (HAMD-17) score from baseline to 8 weeks

Change of Hamilton Depression Rating Scale-17 (HAMD-17) score from baseline to 8 weeks, range: 0-51, higher score means more severe symptom of depression

Time frame: Week 8

Clinical outcome: Number of Participants with remitters and non-remitters

Remitters: Hamilton Depression Rating Scale (HAMD-17)≤7, non-remitters: Hamilton Depression Rating Scale (HAMD-17)≥8

Time frame: Week 8

functional-connectivity

functional-connectivity from functional-MRI

Time frame: baseline and week8

neurite density

neurite density from Neurite Orientation Dispersion and Density Imaging (NODDI)

Time frame: baseline and week8

Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts